The Bundeskartellamt, Germany's competition authority, has officially discontinued its proceedings regarding the proposed acquisition of JenaValve Technology Inc. by Edwards Lifesciences Corporation. This decision follows the notification of the merger in September 2024.

Upon review, the Bundeskartellamt found that the transaction did not meet the national notification thresholds required for merger control. Although the value of the proposed acquisition exceeded 400 million euros, which could have triggered scrutiny under the transaction value threshold, the authority determined that JenaValve did not have substantial operations in Germany at the time of the acquisition.

JenaValve specializes in developing innovative heart valves aimed at treating aortic regurgitation, while Edwards is recognized as a global leader in medical innovations for structural heart disease. The lack of substantial operations in Germany by JenaValve was a critical factor in the authority's decision to discontinue the merger proceedings.